1Borgia F, Giuffrida R, Guarneri F, Cannavò SP. Relapsing Polychondritis: An Updated Review. Biomedicines. 2018;6.
2Mertz P, Costedoat-Chalumeau N, Ferrada MA, et al. Relapsing polychondritis: clinical updates and new differential diagnoses. Nat Rev Rheumatol. 2024;20:347-360.
3Zeuner M, Straub RH, Rauh G, Albert ED, Schölmerich J, Lang B. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 1997;24:96-101.
4Alsalameh S, Mollenhauer J, Scheuplein F, et al. Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. J Rheumatol. 1993;20:1419-24.
5Yang CL, Brinckmann J, Rui HF, et al. Autoantibodies to cartilage collagens in relapsing polychondritis. Arch Dermatol Res. 1993;285:245-9.
6Foidart JM, Abe S, Martin GR, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med. 1978;299:1203-7.
7Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med. 1998;129:114-22.
8Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford). 2006;45:491-2.
9Wendling D, Govindaraju S, Prati C, Toussirot E, Bertolini E. Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine. 2008;75:622-4.
10Moulis G, Sailler L, Astudillo L, Arlet P. Abatacept for relapsing polychondritis. Rheumatology (Oxford). 2010;49:1019.
11Moulis G, Sailler L, Pugnet G, Astudillo L, Arlet P. Biologics in relapsing polychondritis: a case series. Clin Exp Rheumatol. 2013;31:937-9.
12Ferrada MA, Sikora KA, Luo Y, et al. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol. 2021;73:1886-95.
13Arnaud L, Costedoat-Chalumeau N, Mathian A, et al. French practical guidelines for the diagnosis and management of relapsing polychondritis. Rev Med Interne. 2023;44:282-94.
14Moulis G, Pugnet G, Costedoat-Chalumeau N, et al. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Ann Rheum Dis. 2018;77:1172-8.
15Handa H, Ooka S, Shimizu J, Suzuki N, Mineshita M. Evaluation of airway involvement and treatment in patients with relapsing polychondritis. Sci Rep. 2023;13:8307.
16Petitdemange A, Sztejkowski C, Damian L, et al. Treatment of relapsing polychondritis: a systematic review. Clin Exp Rheumatol. 2022;40(Suppl 134):81-5.
17Yoshida T, Nishimura K, Murabe H, Yokota T. Dapsone-induced methaemoglobinaemia in relapsing polychondritis. BMJ Case Rep. 2022;15.
18Heiblig M, Ferrada MA, Koster MT, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140:927-31.
19Comont T, Heiblig M, Rivière E, et al. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol. 2022;196:969-74.
20Hellmich B, Hering S, Duchna HW, et al. Atemwegsbeteiligung bei Rezidivierender Polychondritis. Zeitschrift für Rheumatologie. 2003;62:73-9.
21Wu S, Sagawa M, Suzuki S, et al. Pulmonary Fibrosis with Intractable Pneumothorax: New Pulmonary Manifestation of Relapsing Polychondritis. Tohoku J Exp Med. 2001;194:191-5.
22Wang S, Jiao Y. Mediastinal emphysema: a rare respiratory complication of relapsing polychondritis. BMJ Case Rep. 2013;2013.